Who is sponsoring NCT06023511?

NCT06023511 is sponsored by Health Discovery Labs.

What drugs are being tested in NCT06023511?

Interventions in NCT06023511: Electrical muscle stimulation.

What condition does NCT06023511 study?

NCT06023511 studies ICU Acquired Weakness.

Is NCT06023511 still recruiting?

NCT06023511 is currently completed. Last updated 26 September 2023.

Last reviewed 2023-09-26 · How we verify

NCT06023511

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Safety and Efficacy of the MyokinE100 (CL-EMS Alpha) Device in Inducing Visible Muscle Contraction in Healthy Volunteers

Completed NA Last updated 26 September 2023

What this trial tests

NA trial testing Electrical muscle stimulation in ICU Acquired Weakness in 8 participants. Completed in 23 August 2023.

Timeline

22 August 2023

Primary endpoint
23 August 2023

23 August 2023

Quick facts

Lead sponsor	Health Discovery Labs
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	device feasibility
Enrollment	8
Start date	22 August 2023
Primary completion	23 August 2023
Estimated completion	23 August 2023
Sites	1 location across United States

Drugs / interventions tested

Electrical muscle stimulation

Conditions studied

ICU Acquired Weakness — all drugs for ICU Acquired Weakness →

Sponsor

Health Discovery Labs

Who can join

Adults 18 to 65, any sex, with ICU Acquired Weakness. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Every patient admitted to the Intensive Care Unit (ICU) is at risk of developing "Intensive Care Unit Acquired Weakness" (ICUAW). ICUAW is associated with increased rate of mortality, prolonged duration of mechanical ventilation, ICU and hospital stay, rehabilitation time, and reduced quality of life. Currently, there is no effective treatment for ICUAW. Health Discovery Labs is conducting a research study to evaluate the safety of using an innovative experimental medical device in ICU settings that could mitigate ICUAW. This study is meant to demonstrate whether this new device interferes with standard ICU monitors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Electrical muscle stimulation

Trials testing the same drug.

NCT06613620 — Additional Effects of Surface Electromyographic Biofeedback on Post Facilitation Stretching and Strengthening in Lower C · NA · completed
NCT05341778 — Effects of Pilates Exercises Versus Pelvic Floor Muscle Exercises Among Elderly Women With Urinary Incontinence · NA · completed
NCT03496025 — Facial Function Reanimation by Electrical Pacing in Unilateral Facial Paralysis. · Phase 1 · unknown

Other recruiting trials for ICU Acquired Weakness

Currently open trials in the same condition.

NCT07167121 — Predictive Validity of the Chelsea Critical Care Physical Assessment Tool (CPAx) for Regaining Autonomy Three Months Aft · recruiting
NCT07162948 — ICU-Recover Box 2.0, Smart Technology for Home Monitoring of ICU Patients · NA · recruiting
NCT06592144 — TESTO-TRIAL: Use of Testosterone in Critically Ill Patients · Phase 4 · active not recruiting
NCT05919940 — Improved Muscle Metabolism by Combination of Muscle Activation and Protein Substitution ( IMEMPRO ) · NA · recruiting
NCT05865314 — Optimised Nutritional Therapy and Early Physiotherapy in Long Term ICU Patients (NutriPhyT Trial) · NA · recruiting

Other Health Discovery Labs trials

Trials by the same sponsor.

NCT07362862 — MyokinE100 System: Closed Loop Electrical Muscle Stimulation to Mitigate ICU Acquired Weakness in Medical ICU Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06023511 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Health Discovery Labs
Last refreshed: 26 September 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06023511.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing